TOTAL VOLUME:
$95.2b
24H VOL:
$181,744,002
24H TRANSACTIONS:
920,787,070
OPEN INTEREST:
$1,998,860,640
797,283
Markets across
13,518
events
MATCHED EVENTS:
779
PLATFORM COVERAGE:
5
Polymarket:
45%
VS.
Kalshi:
55%
FDA approves Otsuka's Centanafadine? Odds & Prediction Markets
69%
chance
Time left: 11d:00h:56m
FDA approves Otsuka's Centanafadine?
$
$20
$50
$100
$500
Description
As of market creation, the FDA's expected decision date for the specified application is July 24, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Otsuka's Centanafadine as a treatment for ADHD in children, adolescents, and adults by August 7, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is July 24, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Otsuka's Centanafadine as a treatment for ADHD in children, adolescents, and adults by August 7, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds often diverge from traditional analyst forecasts because they incorporate real-time trader conviction and financial incentives absent from published research. While pharmaceutical analysts may issue cautious or delayed assessments based on limited data releases, this market prices in leaked trial results, regulatory feedback, and competitive landscape shifts as soon as participants trade on them. Comparing the current odds to recent equity research or FDA guidance statements can reveal whether the market is pricing in optimism or skepticism that mainstream forecasters have not yet reflected.
On Polymarket, traders buy and sell shares representing approval or rejection, with the price of each outcome reflecting its implied probability. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The market price adjusts continuously as new information surfaces—such as clinical trial announcements, regulatory meeting minutes, or competitive drug approvals—and traders rebalance their positions. Higher trading volume typically narrows bid-ask spreads and increases price accuracy, while lower volume can create wider gaps and more volatile swings.
This market resolves around Jul 24, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. Resolution hinges on whether the FDA issues an approval decision for Centanafadine by that date. Traders should monitor FDA communications, company press releases, and regulatory calendars for official announcements that will trigger settlement.
Key catalysts include FDA advisory committee meetings, clinical trial data releases, competitive drug approvals or rejections, and official FDA communications regarding Centanafadine's review timeline. Positive Phase III efficacy or safety data typically strengthens approval odds, while safety concerns or requests for additional studies weaken them. Regulatory precedent—such as FDA decisions on similar ADHD or depression treatments—can also shift trader expectations. Company earnings calls and investor presentations may reveal new trial milestones or regulatory feedback that reshape market sentiment.
Follow the signals, not the noise
Get insights on market conviction, notable shifts, and what the data is quietly signaling.